Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 20, 2006

View Archived Issues

Vertex looks ahead to 2006 milestones

HDAC inhibition corrects GABAergic gene promoter deficits for schizophrenia and bipolar disorders

Oridonin inhibits cell growth of leukemic HPB-ALL cells

Piclozotan pharmacokinetics, tolerability evaluated in acute stroke patients

Geron and Cambrex sign manufacturing agreement for GRN-VAC1

Chelsea Therapeutics' private placement to fund development of CH-1504

Monogram Biosciences collaborates with Dana-Faber Cancer Institute

Second closing of Series C financing at Acologix

New phase I/II study investigates intravenous zileuton for asthma

Methylnaltrexone shows rapid response in treating opioid-induced constipation

New orally available interferon inducer from Dainippon Sumitomo

Biota begins phase I safety trials of BTA-798 for common cold

Speedel announces new series of renin inhibitors

GlaxoSmithKline to acquire Pliva Research-Institute

SPA agreement for Remoxy phase III trial

Pain candidate from Merck-Neurogen alliance begins phase I trials

Organon to close LIFT study of tibolone in elderly osteoporotic patients

Survival benefit linked to estrogen in women treated with Xyotax

Snapshot of therapeutic control of inflammation in stroke

Novel analgesic agents disclosed in recent Vertex patent

Recent patents cover novel treatments for anxiety, depression, psychosis, etc.

Engineered component antigen enhances CTL responses for HIV vaccines

Roche files Herceptin for early-stage HER2-positive breast cancer in E.U.

NDA submission for Bio-E-Gel to treat moderate to severe hot flashes

Neuroprotective action of a HIF prolyl hydroxylase inhibitor may be beneficial in stroke

New anti-HIV drug targeting HIV-1 envelope maturation presented by Pfizer

Kureha presents data on its new chemokine CXCR4 antagonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...